Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant

Transplantation

Volumn 86, Issue 3, 2008, Pages 371-376

  Opelz, Gerhard ^a   Döhler, Bernd ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Calcineurin inhibitors; Dose reduction; Kidney transplant; Maintenance immunosuppression; Mycophenolic acid

Indexed keywords

CREATININE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; GRAFT REJECTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; METABOLISM; MULTICENTER STUDY; POSTOPERATIVE CARE; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

CREATININE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; POSTOPERATIVE CARE; RISK ASSESSMENT; RISK FACTORS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 52049085352     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31817fdddb     Document Type: Article

References (19)

1. Kirk AD, Mannon RB, Swanson SJ, et al. Strategies for minimizing immunosuppression in kidney transplantation. Transpl Int 2005; 18: 2.
2. Guerra G, Srinivas TR, Meier-Kriesche HU. Calcineurin inhibitor-free immunosuppression in kidney transplantation. Transpl Int 2007; 20: 813.
3. Salvadori M, Rosati A, Bertoni E, et al. Low 1-year cyclosporine microemulsion doses are associated with better 5-year renal graft function: An insight from MOST, a multinational observational study. Transplant Proc 2006; 38: 1010.
4. Nankivell BJ, Borrows RJ, Fung CL-S. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557.
5. Opelz G, Döhler B. Cyclosporine and long-term kidney graft survival. Transplantation 2001; 72: 1267.
6. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6: 1111.
7. Keown P, Landsberg D, Halloran P, et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine micro-emulsioninstable renal graft recipients. Report ofthe Canadian Neoral Renal Transplantation Study Group. Transplantation 1996; 62: 1744.
8. Kuypers DR, Claes K, Evenepoel P, et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids:Aprospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet 2004; 43: 741.
9. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.
10. Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation 2002; 72: 775.
11. Krämer BK, Montagnino G, del Castillo D, et al. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation:2 year follow-up results.Nephrol Dial Transplant2005; 20: 968.
12. Abouljoud MS, Kumar MS, Brayman KL, et al., for the OLN-452 Study Group. Neoral® rescue therapy in transplant patients with intolerance to tacrolimus. Clin Transplant 2002; 16: 168.
13. Knoll GA, MacDonald I, Khan A, et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381.
14. Hardinger KL, Brennan DC, Lowell J, et al. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 2004; 17: 609.
15. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17: 200.
16. Jain A, Kahshyap R, Dodson F, et al. A prospective randomized trial of tacrolimus and prednisolone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: A single center report. Transplantation 2001; 72: 1091.
17. Budde K, Knoll G, Curtis J, et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic) Clin Nephrol 2006; 66: 103.
18. Salvadori M, Holzer H, Civati G, et al.; ERL B301 Study Group. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients. Clin Nephrol 2006; 66: 112.
19. Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006; 82: 102.